Roche Pegasys Has 23% Market Share; Better Luck In Rematch With Intron? 

Roche's Pegasys has captured a 23% share of new prescriptions for hepatitis C in the U.S., Global Pharmaceutical Head William Burns told investors during a year-end conference in London Feb. 26